N calculation for trial about PK superiority [Power / Sample Size]

posted by dshah  – India, 2022-09-02 13:52 (966 d 10:27 ago) – Posting: # 23262
Views: 3,980

Hi Alex!

I am wondering why PK superiority? I am not getting if you do not prove faster onset of action with PD superiority, you can have advantage. Already the discussion for Tmax assessment (EMA PSG) is discussed in forum. Could you provide more details for not focusing on PD superiority?
Regards,
Divyen Shah

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,668 registered users;
34 visitors (0 registered, 34 guests [including 7 identified bots]).
Forum time: 00:19 CEST (Europe/Vienna)

It is a well-known experience that the only truly enjoyable and
profitable way of studying mathematics is the method of
“filling in details” by one’s own efforts.    Cornelius Lanczos

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5